We examined how SYNGR4 impacts the outlook for breast cancer by studying its correlation with OS (overall survival) (HR=1.59, P=0.004) (Figure 1F), DSS (disease specific survival) (HR=1.74, P=0.011) (Figure 1G), and PFI (progress free interval) (HR=1.64, P=0.003) (Figure 1H) in patients with breast cancer. Here, SYNGR4 is linked to breast cancer.